BRD4 and ovarian cancer: In order to assess the relationship between BRD4 amplification or expression level and sensitivity towards BRD4 inhibition, we utilized Sanger cell line screening data, which provided a 3-day JQ1 IC50 on 12 ovarian cancer cell lines [39].